Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Different Neisseria meningitidis Serogroup C Conjugate Vaccines
- 1 April 2009
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 28 (4) , S77-S88
- https://doi.org/10.1097/inf.0b013e318199f609
Abstract
Immunogenicity of the candidate 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed when coadministered with other routine pediatric vaccines including different Neisseria meningitidis serogroup C conjugate vaccines. One thousand five hundred forty-eight healthy infants received, according to a balanced (1:1:1:1) randomization, either PHiD-CV coadministered with (1) DTPa-HBV-IPV/Hib (Infanrix hexa) and MenC-CRM (Meningitec), (2) DTPa-HBV-IPV/Hib and MenC-TT (NeisVac-C), or (3) DTPa-HBV-IPV (Infanrix penta/Pediarix) and Hib-MenC-TT (Menitorix); or 7vCRM (Prevenar/Prevnar) coadministered with DTPa-HBV-IPV and Hib-MenC-TT at 2-4-6 months of age with a booster dose at 11-18 months. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic (OPA) assay. In all 3 coadministration groups, PHiD-CV was immunogenic for each of the 10 pneumococcal vaccine serotypes as assessed by post-primary and post-booster antibody ELISA and OPA responses. When coadministered with DTPa-HBV-IPV, Hib, and MenC antigens, PHiD-CV responses after the third primary dose were within the same range as 7vCRM responses in terms of the percentage of subjects achieving an ELISA antibody concentration >or=0.2 microg/mL for all common vaccine serotypes (over 92% of subjects) except for serotype 6B (at least 87% of subjects). ELISA and OPA immune responses were also evident after the second primary doses of PHiD-CV or 7vCRM vaccine, although antibody levels were below that achieved after 3 primary doses, particularly for serotypes 6B and 23F. The kinetics of the immune responses from after the second dose to after the booster dose were similar for most of the serotypes in both PHiD-CV and 7vCRM groups. PHiD-CV was immunogenic when coadministered with other routine pediatric vaccines including MenC conjugate vaccines.Keywords
This publication has 36 references indexed in Scilit:
- Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean regionInternational Journal of Antimicrobial Agents, 2007
- Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy studyThe Lancet, 2006
- Middle Ear Fluid Streptococcus pneumoniae Serotype Distribution in Costa Rican Children with Otitis MediaThe Pediatric Infectious Disease Journal, 2005
- Microbiology of otitis media in Costa Rican children, 1999 through 2001The Pediatric Infectious Disease Journal, 2003
- Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae?The Pediatric Infectious Disease Journal, 2003
- Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of lifeThe Pediatric Infectious Disease Journal, 2001
- Bacterial and viral etiology of acute otitis media in Chilean childrenThe Pediatric Infectious Disease Journal, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001
- Effects on the Ciliated Epithelium of Protein D–Producing and –Nonproducing NontypeableHaemophilus influenzaein Nasopharyngeal Tissue CulturesThe Journal of Infectious Diseases, 1999
- Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesteraseJournal of Bacteriology, 1993